SCHEMBL24036747

SCHEMBL24036747

COC(=O)C[C@H](NC(=O)CNC(=O)OC(C)(C)C)c1cccc(C(F)(F)F)c1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GPR139 Q6DWJ6 1/20 0.46
AURKB Q96GD4 1/20 0.45
SLC6A9 P48067 1/20 0.44
HTRA1 Q92743 1/20 0.40
RXFP1 Q9HBX9 1/20 0.39
ITGB3 P05106 1/20 0.39
ITGB1 P05556 1/20 0.39
ITGAV P06756 1/20 0.39
ITGA5 P08648 1/20 0.39
ITGB5 P18084 1/20 0.39
ITGB6 P18564 1/20 0.39
ITGB8 P26012 1/20 0.39
ITGA8 P53708 1/20 0.39
SMN1; SMN2 Q16637 2/20 0.39
MEN1 O00255 1/20 0.39
LMNA P02545 1/20 0.39
POLB P06746 1/20 0.39
HTT P42858 1/20 0.39
KMT2A Q03164 1/20 0.39
HDAC1 Q13547 2/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20743557 0.90 FAAH (0.45) RXFP1SMN1; SMN2MEN1LMNAPOLB
SCHEMBL25624224 0.89 ITGB3 (0.39) GPR139AURKBSLC6A9ITGB3ITGB1
SCHEMBL24036746 0.88 GPR139 (0.39) GPR139ITGB3ITGAVITGB5ITGB6
SCHEMBL24036706 0.87 THRB (0.42) GPR139AURKBSLC6A9MEN1POLB
SCHEMBL24036750 0.87 GPR139 (0.50) GPR139ITGB3ITGAVITGB5ITGB6
SCHEMBL25624830 0.86 GPR139 (0.42) GPR139SLC6A9ITGB3ITGAVITGB5
SCHEMBL24036744 0.86 ITGB3 (0.40) GPR139ITGB3ITGAVITGB5ITGB6
SCHEMBL24036910 0.86 ITGB3 (0.47) GPR139AURKBSLC6A9ITGB3ITGB1
SCHEMBL24036908 0.86 MAPT (0.38) GPR139AURKBSLC6A9ITGB3ITGB1
SCHEMBL24036907 0.86 ITGB3 (0.37) GPR139AURKBSLC6A9ITGB3ITGB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230192661-A1 1, 4, 5, 6-TETRAHYDROPYRIMIDINE-2-AMINE DERIVATIVE UBE CORPORATION (JP) 2023-06-22 US disclosed
WO-2023085396-A1 PHARMACEUTICAL COMPOSITION FOR PROVIDING TREATMENT FOR OR PREVENTING ALPORT SYNDROME UBE株式会社 2023-05-19 WO disclosed
WO-2021230325-A1 1, 4, 5, 6-TETRAHYDROPYRIMIDINE-2-AMINE DERIVATIVE 宇部興産株式会社 2021-11-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230192661-A1 1, 4, 5, 6-TETRAHYDROPYRIMIDINE-2-AMINE DERIVATIVE DHFR, DPYD, CYP2D6 GPR139 676/4885AURKB 2072/4885SLC6A9 1426/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.